Bioventix PLC - London-based biotechnology company - Posts pretax profit of GBP8.2 million for the year ended June 30, up 18% from GBP6.9 million the year prior. Revenue rises 11% to GBP10.3 million as sales of the company's vitamin D antibody vitD3.5H10 increased by 10% to GBP4.8 million. Declares a second interim dividend of 52 pence, up from 43p the year prior, taking the total annual dividend to 88p. Full year dividend payout for financial 2019 was 73p. Declares a special dividend of 53p, up from last year's special dividend of 47p. Confident in robustness of business amid Covid-19 uncertainty. Cash held as at June end was GBP8.1 million.
Current stock price: 4,280.00p
Year-to-date change: up 29%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Bioventix (BVXP)